desk
Share
Alembic Pharma has received US Drug and Administration (USFDA) approval for Diltiazem Hydrochloride Extended-Release Capsules used to treat high blood pressure and prevent chest pain. In an exchange filing, the company said that the company has received final approval from the USFDA for Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg and 240 mg.
The company said in the release that according to IQVIA, the estimated market size of Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg and 240 mg for the twelve months ending June 2024 is US$ 28.2 million. Alembic has a total of 217 ANDA approvals (190 final approvals and 27 tentative approvals) from the USFDA.
Stock performance On Friday, the company's stock closed down 2.39 per cent at Rs 1,157. In the last one year, the company's stock has seen a rise of 44.95 per cent. The 52-week high of the stock is Rs 1,303.90.
--Advertisement--
